Background {#Sec1}
==========

Inflammation plays a key role in the occurrence and development of atherosclerosis \[[@CR1]\]. The neutrophil to lymphocyte ratio (NLR) is an indicator of systemic inflammation and a prognostic marker in patients undergoing percutaneous coronary intervention (PCI) \[[@CR2], [@CR3]\]. Furthermore, in previous studies, the NLR has been demonstrated to be related to in-hospital cardiovascular mortality and long-term mortality in patients with ST segment elevation myocardial infarction (STEMI) \[[@CR4], [@CR5]\]. However, the results of individual studies were different. Our meta-analysis aimed to evaluate the relationship between NLR and in-hospital or long-term prognosis of patients with STEMI after PCI.

Methods {#Sec2}
=======

Study search strategy {#Sec3}
---------------------

A systematic search was conducted in the English-language databases of Pubmed, Embase, and Ovid (from inception to June 2017) for studies regarding in-hospital or long-term prognosis of patients with NLR and STEMI after PCI. According to the language of the databases, we used the appropriate search strategy. ("Neutrophils to lymphocytes ratio," or "NLR" or "neutrophils lymphocytes ratio") and ("ST Segment Elevation Myocardial Infarction," or "ST Elevated Myocardial Infarction," or "STEMI") and ("Percutaneous coronary intervention," or "PCI") in the title or abstract terms were used as key words for the English-language databases.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Studies were included if they met the following criteria: (1) the subjects were STEMI receiving primary PCI; (2) the study types were prospective cohort study or retrospective cohort study; and (3) risk estimates of association between NLR levels and cardiovascular related events occurring during hospital or follow-up were studied experimentally. Tests that did not meet all of the above criteria were excluded.

Data extraction {#Sec5}
---------------

Study searches and the data extraction of the included studies were conducted independently by two researchers. The quality of each study was evaluated independently using the Newcastle-Ottawa Scale \[[@CR6]\]. This scale uses a star system to evaluate nonrandomized studies regarding 3 criteria: patient selection, comparability of study groups, and outcome assessment. Studies achieving a rating of 6 stars or higher were considered to be of the highest quality. The basic information include domains of authors, year of publication, age of target participant, comparison of NLR, number of events, sample size, and the follow-up period. If the articles were ambiguous or lacking of outcomes, we contacted the author. If the author was not available, we extracted the relevant data through consensus.

Statistical analysis {#Sec6}
--------------------

Data analyses were performed using Version 5.3 Review Manager statistical software. Heterogeneity among studies was assessed using χ^2^ and *I*^2^ statistics. *I*^2^ **≤** 50% suggests that heterogeneity is not statistically significant. *I*^2^ \> 50% indicates the presence of heterogeneity, and heterogeneity analysis will be further performed. If there was no significant heterogeneity between studies, the fixed-effect model was used. Otherwise, the random effects model was applied. Publication bias was indicated by a funnel plot. The value *P* \< 0.05 was considered to be statistically significant.

Results {#Sec7}
=======

Search results {#Sec8}
--------------

A total of 265 potential relevant studies were selected from electronic databases, 251 were excluded as they did not meet the inclusion criteria. 14 studies were finally considered for this study. The studies selection process is shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow chart of literatures screening and the reasons for exclusion

Study characteristics {#Sec9}
---------------------

Table [1](#Tab1){ref-type="table"} demonstrates the basic features of the studies. A total of 14 studies from 6 countries were included in our analysis, of which 12 \[[@CR7]--[@CR18]\] were prospective cohort studies, and 2 \[[@CR19], [@CR20]\] were retrospective cohort studies. Han \[[@CR9]\], He \[[@CR10]\] and Ergelen \[[@CR19]\] have less than six stars. Akpek \[[@CR7]\] and Kaya \[[@CR13]\] are multi-country study and the others are single-country study. A total of 10,245 patients were enrolled, including 7908 males. The follow-up time was 3.8 days to 3395 days.Table 1Characteristics of included studies and quality evaluation of documentsStudyStudyCountrymale,%Age\
mean(SD)NLR\
groupingFollow-up\
(days)Observation indexQuality\
scoreAkpek, \[[@CR7]\] 2012Prospective cohort studyTurkey,\
China,\
USA327(78.0)59.4 ± =12.4≤3.3\
\> 3.36.7(mean)In-hospital: in-stent thrombosis, MACE, nonfatal MI,\
no reflow, all-cause mortality6Arbel, \[[@CR8]\] 2014Prospective cohort studyIsrael436(81.0)61 ± 13\<  6.5\
≥6.51044 (median)In-hospital: arrhythmia\
Long-term: all-cause mortality6Han, \[[@CR9]\]\
2013Prospective cohort studyKorea247(75.8)61.9 ± 12.3≤3.30\
3.31--6.52\
\> 6.53360(total)In-hospital: MACE, nonfatal MI, no reflow, all-cause mortality\
Long-term: nonfatal MI, MACE, all-cause mortality5He, \[[@CR10]\]\
2014Prospective cohort studyChina546(78.9)60.27\< 3.16\
3.16--4.75\
\> 4.753395 (median)In-hospital: arrhythmia, no reflow, cardiac mortality, all-cause mortality\
Long-term: cardiac mortality, all-cause mortality, MACE5Her, \[[@CR11]\]\
2017Prospective cohort studyKorea140(81.4)57.1 ± 12.4\< 5.8\
≥5.81230(median)In-hospital: MACE\
12 months follow-up: MACE,\
Long-term: all-cause mortality, nonfatal MI6Park JinJoo,\
2013 \[[@CR12]\]Prospective cohort studyKorea235(72.0)60.9 ± 13.9\< 5.44\
≥5.441092(median)Long-term: all-cause mortality6Kaya, \[[@CR13]\] 2013Prospective cohort studyTurkey,\
China,\
USA535(78.4)60.8\< 2.3\
2.3--4.4\
\> 4.41299(median)In-hospital: in-stent thrombosis, MACE, non-fatal MI, no reflow,\
cardiac mortality,\
Long-term: Non-fatal MI,MACE, cardiac mortality6Pan, \[[@CR14]\]\
2015Prospective cohort studyChina496(78.0)59.27 ± 11.27\<  3.0\
3.0--6.40\
\>  6.40360(total)In-hospital: angina, arrhythmia, cardiac mortality,\
12 months follow-up: all-cause mortality6Sen, \[[@CR15]\] 2013Prospective cohort studyTurkey176(86.3)55.8\<  3.30\
3.30--4.56\
\> 4.561140 (total)In-hospital: all-cause mortality, MACE, no reflowAt three-year follow up, all-cause mortality, MACE6Shen, \[[@CR16]\]\
2010Prospective cohort studyChina329(59.7)611.44--3.45\
3.45--4.81\
4.82--6.46\
6.47--22.571898 (median)In-hospital: all-cause mortality\
Long-term: all-cause mortality6Tanriverdi, \[[@CR17]\] 2017Prospective cohort studyTurkey285(77.4)59.6\< 5.47\
≥ 5.473.8(mean)In-hospital: all-cause mortality6Zuin, \[[@CR18]\] 2017Prospective cohort studyItaly1724(71.8)64.5\< 2.1\
3.4--4.1\
\> 4.1363(median)Long-term: cardiovascular mortality6Ergelen, \[[@CR19]\] 2014Retrospective cohort studyTurkey2015(83.6)56.4≤6.97\
\> 6.97630 (median)In hospital: AHF, MACE, nonfatal MI, no reflow, cardiovascular mortality,\
Long-term: MACE, nonfatal MI, cardiovascular mortality5Gazi, \[[@CR20]\] 2015Retrospective cohort studyTurkey417(79.9)62.57≤5.77\
\> 5.775.7(mean)In-hospital: AHF, angina, arrhythmia, all-cause mortality, nonfatal MI6

Incidence of mortality and cardiovascular events {#Sec10}
------------------------------------------------

Based on heterogeneity, the fixed effects model was applied to in-hospital cardiac mortality (*P* \< 0.001; relative risk (RR) 3.22; 95% confidence interval (CI) 2.25--4.60), in-hospital all mortality (*P* \< 0.001; RR3.23; 95% CI 2.28--4.57), long-term all mortality (*P* \< 0.001; RR 3.82; 95% CI 2.94--4.96), in-hospital major adverse cardiovascular events (MACE) (*P* \< 0.001; RR 2.00; 95%CI 1.62--2.46), in-stent thrombosis (*P* \< 0.001; RR2.72; 95% CI 1.66--4.44), in-hospital nonfatal MI (*P* \< 0.001; RR 1.93; 95% CI 1.43--2.61), angina (*P* = 0.007; RR 1.67; 95% CI 1.15--2.41), AHF (*P* \< 0.001; RR 1.81; 95% CI 1.48--2.21), and arrhythmia (*P* = 0.002; RR 1.38; 95% CI 1.13--1.69). Meanwhile, the random effects model was used for mortality (*P* \< 0.001; RR 3.32; 95%CI 2.45--4.49), long-term cardiac mortality (*P* = 0.004; RR 3.02; 95% CI 1.41--6.45), long-term MACE (*P* \< 0.001; RR 2.49; 95% CI 1.47--4.23), long-term nonfatal MI (*P* = 0.46; RR 1.32; 95% CI 0.63--2.75), and no reflow (*P* \< 0.001; RR 2.28; 95% CI 1.46--3.57). No significant difference was observed for long-term nonfatal MI (*P* = 0.46; RR 1.32; 95% CI 0.63--2.75) (Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}; Table [2](#Tab2){ref-type="table"}, and Additional file [1](#MOESM1){ref-type="media"}, Additional file [2](#MOESM2){ref-type="media"}, Additional file [3](#MOESM3){ref-type="media"}, Additional file [4](#MOESM4){ref-type="media"}, Additional file [5](#MOESM5){ref-type="media"}, Additional file [6](#MOESM6){ref-type="media"}, Additional file [7](#MOESM7){ref-type="media"}, Additional file [8](#MOESM8){ref-type="media"}, Additional file [9](#MOESM9){ref-type="media"}, Additional file [10](#MOESM10){ref-type="media"}, Additional file [11](#MOESM11){ref-type="media"}, Additional file [12](#MOESM12){ref-type="media"}).Fig. 2Comparing the mortality between high NLR groups and the low NLR groupsFig. 3Comparing the long-term cardiac mortality between high NLR groups and the low NLR groupTable 2Results of high NLR and low NLR mortality rates and cardiovascular eventsOutcomesIncluded studiesHeterogeneityTest for overall effectχ^2^PI^2^(%)ZPRR 95%CIIn-hospital AHF19,201.540.22355.81\< 0.000011.81\[1.48,2.21\] Angina**14,20**0.080.7802.710.0071.67\[1.15,2.41\] Arrhythmia8, 10,14,200.820.8403.140.0021.38\[1.13,1.69\] In-stent thrombosis7,130.030.8603.99\< 0.00012.72\[1.66,4.44\] MACE7,9,11,13,15,193.830.5706.53\< 0.000012.00\[1.62,2.46\] Nonfatal MI7,9,13,19,204.880.30184.32\< 0.00011.93\[1.43,2.61\] No reflow7,9,10,13,15,1940.00\< 0.00001873.630.00032.28\[1.46,3.57\] All mortality7,9,10,15,17,201.870.8706.61\< 0.000013.23\[2.28,4.57\] Cardiac mortality10,13,14,16,191.770.7806.42\< 0.000013.22\[2.25,4.60\]Long-term Nonfatal MI9, 11,13,19,10.900.01720.750.461.32\[0.63,2.75\] MACE9,10,11,13,15,1953.33\< 0.00001913.390.00072.49\[1.47,4.23\] All mortality8,9,10,11,12,14,153.850.70010.06\< 0.000013.82\[2.94,4.96\] Cardiac mortality10,13,16,18,1943.78\< 0.00001912.850.0043.02\[1.41,6.45\]

Heterogeneity analysis {#Sec11}
----------------------

Analyses with *I*^2^ \> 50%, including death, no reflow, long term nonfatal MI, MACE, and cardiac mortality, we conducted a subgroup analysis. The results showed that heterogeneity may come from the time of patient follow- up, race, type of study, etc.

Publication bias {#Sec12}
----------------

No bias was found in the results of 14 studies on funnel plots of mortality risk.(Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Funnel plot results of 14 studies according to the risk of mortality

Discussion {#Sec13}
==========

The results of our meta-analysis show that the high NLR group has a higher risk of angina, advanced HF, arrhythmia, MACE, cardiac mortality, all mortality, in-stent thrombosis, nonfatal MI, and no reflow than the low NLR group during hospitalization. In addition, the risk of long-term mortality, cardiac mortality and MACE in the high NLR group was higher than that of the low NLR group. However, no significant difference was observed for long-term nonfatal MI.

Wang \[[@CR21]\] and Zhang \[[@CR22]\] reported a meta-analysis, which discussed the predictive value of NLR in patients after angiography or cardiac revascularization. Similar conclusions were drawn from long-term all-cause mortality and several other results. However, this study is significantly different from their studies with regards to the literature inclusion criteria. The trials they selected did not include all patients with acute STEMI who underwent emergency interventional therapy. The time and method of opening blood vessels may affect the prognosis of patients, so we reduce the impact of these factors.

A large number of experiments have demonstrated that inflammatory response plays an important role in the development and progression of acute coronary syndrome (ACS) \[[@CR23], [@CR24]\]. White blood cell plays a vital role in the progression of atherosclerosis and destabilization, leading to thrombotic events \[[@CR25], [@CR26]\]. Increased white blood cell count is associated with an increased mortality for STEMI patients \[[@CR27]\]. However, the total number of leukocytes is easily influenced by race and sex, and it is difficult to establish a reference range for the whole population \[[@CR28]\].

In recent years, in-depth study of the clinical effect of inflammatory reaction in occurrence and development of coronary heart disease observed that different subtypes of leukocytes compared with the total leukocyte count and specific subtype, including neutrophils, lymphocytes and monocytes, have more predictive value in the risk assessment of cardiovascular disease \[[@CR29]\].

Neutrophils are the first white blood cell subsets to be observed in the damaged myocardium and move away from the myocardium after phagocytizing debris \[[@CR16]\]. Neutrophils play an important role in the destabilization of atherosclerotic plaques \[[@CR30]\]. CD4 + T lymphocytes belong to the regulatory arm of the immune system, playing a key role in regulating the inflammatory response at different stages of atherogenesis and acute MI \[[@CR31]--[@CR33]\]. However, neutrophils count is easily affected by the patient's own state, such as blood volume. The CD4 + T lymphocyte counts are not readily available for immediate blood testing.

In recent years, studies have observed that NLR, by combining the change in neutrophils and lymphocytes in the course of inflammation, is a more powerful predictor of cardiovascular disease than any other leukocyte subtypes \[[@CR18], [@CR34], [@CR35]\]. NLR can be obtained from routine blood tests and used as a cost effective biomarker for inflammation. Previous studies observed that NLR as a new inflammatory marker is a good prognostic factor for patients with ACS \[[@CR36], [@CR37]\]. Many studies have observed that high NLR levels have a very important relationship with cardiovascular and all-cause mortality in STEMI patients, during hospitalization or long-term \[[@CR16], [@CR20], [@CR38]\]. In addition, several studies have shown evidence that a higher NLR is associated with a lower ejection fraction after STEMI \[[@CR8], [@CR11]\]. Several studies have also observed that high NLR levels are often associated with complex coronary arteries in patients \[[@CR39], [@CR40]\]. Left ventricular apical thrombus and remodeling were also found to be related to high NLR \[[@CR41], [@CR42]\].

Hence, NLR as a new marker of inflammation might be for the assessment of risk levels in STEMI patients with PCI. However, in order to reduce the incidence of complications and deaths, active treatment may be needed to reduce NLR levels in patients with STEMI, which requires a more rigorous multi-center clinical trial to confirm. There are several limitations in our analysis. First, less relevant experiments was included. Second, different methods may be used for different cell counts. There is no uniform counting standard. Third, the observation indexes of the experiments are different. Several experiments only provided hospital events. Several studies were followed for a short time, while other experiments used telephone follow-up may affect accuracy of the data. Finally, our analysis failed to correct for interference from a number of factors.

Conclusions {#Sec14}
===========

Our meta-analysis showed that NLR levels were related to the hospital and long-term prognosis of patients with STEMI after PCI.
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:   Acute coronary syndrome

AHF

:   Advanced heart failure

CI

:   Confidence interval

MACE

:   Major adverse cardiovascular events

MI

:   Myocardial infarction
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:   Neutrophil to lymphocyte ratio
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:   Percutaneous coronary intervention

RR

:   Relative risk

STEMI

:   ST segment elevation myocardial infarction
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